SCAI Expert Consensus Statement on Percutaneous Coronary Intervention Without On-Site Surgical Backup.

Competing Interests: Funding Support and Author Disclosures Dr Seto has received speaker fees from Terumo and is a consultant for Medtronic. Dr Velagapudi has received travel funding from Boston Scientific and Medtronic; and has received speaker fees from Medtronic. Dr Carr holds equity in an ASC OBL and is a consultant for Abbott. Dr Blankenship is a principal investigator for research on supersaturated oxygen infusion after anterior MI funded by Zoll. Dr Abbott is a consultant for Boston Scientific. Dr Mamas has received speaker fees from Terumo; and is a principal investigator for registry-based research on complex PCI outcomes funded by Abbott. Dr Vidovich holds equity of intellectual property related to catheter technology and is a principal investigator for research on optical coherence tomography in left main funded by Boston Scientific. Dr Kent is a consultant for Medtronic; and is an adviser to Abbott. Dr Curzen is a chief investigator for the RIPCORD 2 (A Randomised Controlled Trial to Compare Routine Pressure Wire Assessment With Conventional Angiography in the Management of Patients With Coronary Artery Disease) trial, funded by Boston Scientific, and the FORECAST (Fractional Flow Reserve Derived From Computed Tomography Coronary Angiography in the Assessment and Management of Stable Chest Pain) trial, funded by HeartFlow; has received research grants from Boston Scientific and Beckmann Coulter; has received speaker fees from Abbott, Boston Scientific, and Edwards Lifesciences; has received travel funds from Biosensors, Medtronic, Edwards Lifesciences, and Boston Scientific; and is a consultant for Abbott, Boston Scientific, and Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.